Acalabrutinib‐related second primary malignancies and nonmelanoma skin cancers in patients with chronic lymphocytic leukaemia (CLL): A systematic review and meta‐analysis of randomised controlled trials (RCTs)
Acalabrutinib is a second generation Bruton's tyrosine kinase inhibitor and was recently approved in the treatment of chronic lymphocytic leukaemia. We undertook a systematic review and meta‐analysis of randomised controlled trials to determine the risks of acalabrutinib‐related second primary...
Saved in:
| Published in | EJHaem Vol. 2; no. 1; pp. 115 - 120 |
|---|---|
| Main Authors | , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
John Wiley & Sons, Inc
01.02.2021
John Wiley and Sons Inc Wiley |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Acalabrutinib is a second generation Bruton's tyrosine kinase inhibitor and was recently approved in the treatment of chronic lymphocytic leukaemia. We undertook a systematic review and meta‐analysis of randomised controlled trials to determine the risks of acalabrutinib‐related second primary malignancies (SPM) and nonmelanoma skin cancers (NMSC). The incidence of SPM was 4.7% higher in the acalabrutinib arm compared to control arm with risk ratio (RR) of 1.76 (5.32 vs 3.2 per 100 person‐years). Notably, NMSC was the most common SPM, and the incidence was 2.56 per 100 person‐years in the acalabrutinib group versus 1.12 per 100 person‐years in the control group (RR 2.43). Long‐term follow‐up and future studies are necessary to define the actual relationship and their risk factors. |
|---|---|
| AbstractList | Acalabrutinib is a second generation Bruton's tyrosine kinase inhibitor and was recently approved in the treatment of chronic lymphocytic leukaemia. We undertook a systematic review and meta-analysis of randomised controlled trials to determine the risks of acalabrutinib-related second primary malignancies (SPM) and nonmelanoma skin cancers (NMSC). The incidence of SPM was 4.7% higher in the acalabrutinib arm compared to control arm with risk ratio (RR) of 1.76 (5.32 vs 3.2 per 100 person-years). Notably, NMSC was the most common SPM, and the incidence was 2.56 per 100 person-years in the acalabrutinib group versus 1.12 per 100 person-years in the control group (RR 2.43). Long-term follow-up and future studies are necessary to define the actual relationship and their risk factors. Abstract Acalabrutinib is a second generation Bruton's tyrosine kinase inhibitor and was recently approved in the treatment of chronic lymphocytic leukaemia. We undertook a systematic review and meta‐analysis of randomised controlled trials to determine the risks of acalabrutinib‐related second primary malignancies (SPM) and nonmelanoma skin cancers (NMSC). The incidence of SPM was 4.7% higher in the acalabrutinib arm compared to control arm with risk ratio (RR) of 1.76 (5.32 vs 3.2 per 100 person‐years). Notably, NMSC was the most common SPM, and the incidence was 2.56 per 100 person‐years in the acalabrutinib group versus 1.12 per 100 person‐years in the control group (RR 2.43). Long‐term follow‐up and future studies are necessary to define the actual relationship and their risk factors. Acalabrutinib is a second generation Bruton's tyrosine kinase inhibitor and was recently approved in the treatment of chronic lymphocytic leukaemia. We undertook a systematic review and meta‐analysis of randomised controlled trials to determine the risks of acalabrutinib‐related second primary malignancies (SPM) and nonmelanoma skin cancers (NMSC). The incidence of SPM was 4.7% higher in the acalabrutinib arm compared to control arm with risk ratio (RR) of 1.76 (5.32 vs 3.2 per 100 person‐years). Notably, NMSC was the most common SPM, and the incidence was 2.56 per 100 person‐years in the acalabrutinib group versus 1.12 per 100 person‐years in the control group (RR 2.43). Long‐term follow‐up and future studies are necessary to define the actual relationship and their risk factors. Acalabrutinib is a second generation Bruton's tyrosine kinase inhibitor and was recently approved in the treatment of chronic lymphocytic leukaemia. We undertook a systematic review and meta-analysis of randomised controlled trials to determine the risks of acalabrutinib-related second primary malignancies (SPM) and nonmelanoma skin cancers (NMSC). The incidence of SPM was 4.7% higher in the acalabrutinib arm compared to control arm with risk ratio (RR) of 1.76 (5.32 vs 3.2 per 100 person-years). Notably, NMSC was the most common SPM, and the incidence was 2.56 per 100 person-years in the acalabrutinib group versus 1.12 per 100 person-years in the control group (RR 2.43). Long-term follow-up and future studies are necessary to define the actual relationship and their risk factors.Acalabrutinib is a second generation Bruton's tyrosine kinase inhibitor and was recently approved in the treatment of chronic lymphocytic leukaemia. We undertook a systematic review and meta-analysis of randomised controlled trials to determine the risks of acalabrutinib-related second primary malignancies (SPM) and nonmelanoma skin cancers (NMSC). The incidence of SPM was 4.7% higher in the acalabrutinib arm compared to control arm with risk ratio (RR) of 1.76 (5.32 vs 3.2 per 100 person-years). Notably, NMSC was the most common SPM, and the incidence was 2.56 per 100 person-years in the acalabrutinib group versus 1.12 per 100 person-years in the control group (RR 2.43). Long-term follow-up and future studies are necessary to define the actual relationship and their risk factors. Abstract Acalabrutinib is a second generation Bruton's tyrosine kinase inhibitor and was recently approved in the treatment of chronic lymphocytic leukaemia. We undertook a systematic review and meta‐analysis of randomised controlled trials to determine the risks of acalabrutinib‐related second primary malignancies (SPM) and nonmelanoma skin cancers (NMSC). The incidence of SPM was 4.7% higher in the acalabrutinib arm compared to control arm with risk ratio (RR) of 1.76 (5.32 vs 3.2 per 100 person‐years). Notably, NMSC was the most common SPM, and the incidence was 2.56 per 100 person‐years in the acalabrutinib group versus 1.12 per 100 person‐years in the control group (RR 2.43). Long‐term follow‐up and future studies are necessary to define the actual relationship and their risk factors. |
| Author | Thein, Kyaw Z. Htut, Thura W. Han, Myat M. |
| AuthorAffiliation | 1 Department of Haematology Aberdeen Royal Infirmary Foresterhill Health Campus Aberdeen United Kingdom 2 Division of Hematology and Medical Oncology Oregon Health and Science University/ Knight Cancer Institute Portland Oregon United States 3 Department of Investigational Cancer Therapeutics The University of Texas MD Anderson Cancer Center Houston Texas United States |
| AuthorAffiliation_xml | – name: 2 Division of Hematology and Medical Oncology Oregon Health and Science University/ Knight Cancer Institute Portland Oregon United States – name: 3 Department of Investigational Cancer Therapeutics The University of Texas MD Anderson Cancer Center Houston Texas United States – name: 1 Department of Haematology Aberdeen Royal Infirmary Foresterhill Health Campus Aberdeen United Kingdom |
| Author_xml | – sequence: 1 givenname: Thura W. orcidid: 0000-0002-5508-1472 surname: Htut fullname: Htut, Thura W. email: thura.winhtut@nhs.scot organization: Foresterhill Health Campus – sequence: 2 givenname: Myat M. surname: Han fullname: Han, Myat M. organization: Oregon Health and Science University/ Knight Cancer Institute – sequence: 3 givenname: Kyaw Z. surname: Thein fullname: Thein, Kyaw Z. organization: The University of Texas MD Anderson Cancer Center |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35846092$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9ks9u1DAQxiNUREupxBMgS1y2hy12_jgOh0qrFdCilZBQOVuzzmTX2yRe7KSr3HgEXo4X4EmYtEtpkeCUL56fPn8znufRQetajKKXgp8JzuM3mzXEZyKVT6KjWCo1laQPHujD6CSEDSc0EZlMxLPoMMlUKnkRH0U_ZgZqWPq-s61d_vz23WMNHZYsoHFtybbeNuAH1kBtVy20xmJgQAUK0RDaugZYuLYtM1REHxjJLXQW2y6wne3WzKy9a61h9dBs184M3aixvwZsLLDJfLE4fctmLAyhwwbGqscbi7vbaxrsgFJBC_UQbGCuYp7OXWMDhaSInXd1TbLzFurAJp_nV-H0RfS0oj882X-Poy_v313NL6aLTx8u57PF1KRxIqepMZnKBZQ5QqY4IK9MYUyeJqoERINS0sSyZZaYuFymZZUYUxSFEVyYDFSeHEeXd76lg43ez0o7sPr2wPmVBk8d1ahlrAygyGUFKs2xBMFTk1R8SUKoWJDX-Z3Xtl82WBoaoIf6kenjSmvXeuVudCFyek5FBpO9gXdfewydpiEZrOmR0PVBx7IQKbVZSEJf_4VuXO9pxiMlCq64kvF_qSwtsiRRifhzrfEuBI_VfWTB9bigelxQTYtI6KuHLd6Dv9eRgOkdsLM1Dv800h8vZvFo-AtRMvdU |
| Cites_doi | 10.1056/NEJMoa1509388 10.1016/S0140-6736(20)30262-2 10.1002/hon.54_2629 10.1517/14656566.9.9.1481 10.1080/10428190310001612939 10.1002/sim.1186 10.1038/leu.2016.113 10.1056/NEJMoa1509981 10.1371/journal.pmed.1000097 10.1182/blood-2007-09-111344 10.1038/s41375-020-0987-6 10.1182/blood-2013-07-515361 |
| ContentType | Journal Article |
| Copyright | 2020 The Authors. published by British Society for Haematology and John Wiley & Sons Ltd. 2020 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd. 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: 2020 The Authors. published by British Society for Haematology and John Wiley & Sons Ltd. – notice: 2020 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd. – notice: 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | 24P WIN NPM AAYXX CITATION 8FE 8FH ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO GNUQQ HCIFZ LK8 M7P PIMPY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1002/jha2.146 |
| DatabaseName | Wiley-Blackwell Titles (Open access) Wiley Online Library PubMed CrossRef ProQuest SciTech Collection ProQuest Natural Science Collection ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection AUTh Library subscriptions: ProQuest Central ProQuest Natural Science Collection ProQuest One Community College ProQuest Central ProQuest Central Student SciTech Premium Collection (Proquest) (PQ_SDU_P3) Biological Sciences Biological Science Database Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals |
| DatabaseTitle | PubMed CrossRef Publicly Available Content Database ProQuest Central Student ProQuest Biological Science Collection ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest Natural Science Collection Biological Science Database ProQuest SciTech Collection ProQuest Central China ProQuest Central ProQuest One Academic UKI Edition Natural Science Collection ProQuest Central Korea Biological Science Collection ProQuest One Academic MEDLINE - Academic |
| DatabaseTitleList | PubMed CrossRef Publicly Available Content Database Publicly Available Content Database MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: 24P name: Wiley-Blackwell Titles (Open access) url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: BENPR name: AUTh Library subscriptions: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| DocumentTitleAlternate | HTUT et al |
| EISSN | 2688-6146 |
| EndPage | 120 |
| ExternalDocumentID | oai_doaj_org_article_628cae176fa847eda104c3f0ba101821 10_1002_jha2_146 35846092 JHA2146 |
| Genre | reviewArticle Journal Article Review |
| GroupedDBID | 0R~ 1OC 24P 53G AAHHS ACCFJ ACXQS ADKYN ADPDF ADZMN AEEZP AEQDE AFKRA AFPKN AIWBW AJBDE ALMA_UNASSIGNED_HOLDINGS ALUQN AVUZU BBNVY BENPR BHPHI CCPQU EBS GROUPED_DOAJ HCIFZ IAO IHR INH M7P M~E OVD OVEED PGMZT PIMPY RPM TEORI WIN ITC NPM AAYXX CITATION 8FE 8FH ABUWG AZQEC DWQXO GNUQQ LK8 PQEST PQQKQ PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c4236-4cc5871ad7ea580ae0fc9cc7438daeece661565b53c2db4df3cc999c101c5a873 |
| IEDL.DBID | RPM |
| ISSN | 2688-6146 |
| IngestDate | Tue Oct 22 15:12:25 EDT 2024 Tue Sep 17 21:23:12 EDT 2024 Sat Oct 26 04:11:22 EDT 2024 Thu Oct 10 18:59:32 EDT 2024 Thu Oct 10 17:55:07 EDT 2024 Thu Sep 26 18:03:07 EDT 2024 Sat Nov 02 12:04:02 EDT 2024 Sat Aug 24 01:04:55 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | chronic lymphocytic leukaemia meta‐analysis nonmelanoma skin cancers second primary malignancies acalabrutinib |
| Language | English |
| License | Attribution 2020 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4236-4cc5871ad7ea580ae0fc9cc7438daeece661565b53c2db4df3cc999c101c5a873 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0002-5508-1472 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175848/ |
| PMID | 35846092 |
| PQID | 2549533831 |
| PQPubID | 5066168 |
| PageCount | 6 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_628cae176fa847eda104c3f0ba101821 pubmedcentral_primary_oai_pubmedcentral_nih_gov_9175848 proquest_miscellaneous_2691458096 proquest_journals_2619080862 proquest_journals_2549533831 crossref_primary_10_1002_jha2_146 pubmed_primary_35846092 wiley_primary_10_1002_jha2_146_JHA2146 |
| PublicationCentury | 2000 |
| PublicationDate | February 2021 |
| PublicationDateYYYYMMDD | 2021-02-01 |
| PublicationDate_xml | – month: 02 year: 2021 text: February 2021 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Hoboken |
| PublicationTitle | EJHaem |
| PublicationTitleAlternate | EJHaem |
| PublicationYear | 2021 |
| Publisher | John Wiley & Sons, Inc John Wiley and Sons Inc Wiley |
| Publisher_xml | – name: John Wiley & Sons, Inc – name: John Wiley and Sons Inc – name: Wiley |
| References | 2008; 9 2016; 30 2016; 374 2020; 34 2003; 327 2009; 6 2008; 112 2020; 395 2019; 37 2004; 45 2014; 123 2015; 373 e_1_2_7_6_1 e_1_2_7_11_1 e_1_2_7_5_1 e_1_2_7_10_1 e_1_2_7_4_1 e_1_2_7_3_1 e_1_2_7_9_1 e_1_2_7_8_1 e_1_2_7_7_1 e_1_2_7_2_1 e_1_2_7_13_1 e_1_2_7_12_1 |
| References_xml | – volume: 374 start-page: 323 year: 2016 end-page: 32 article-title: Acalabrutinib (ACP‐196) in relapsed chronic lymphocytic leukemia publication-title: N Engl J Med – volume: 37 start-page: 86 year: 2019 end-page: 7 article-title: Acalabrutinib vs rituximab plus idelalisib (IdR) or bendamustine (BR) by investigator choice in relapsed/refractory (RR) chronic lymphocytic leukemia: phase 3 ASCEND study publication-title: Hematol Oncol – volume: 123 start-page: 1207 year: 2014 end-page: 13 article-title: Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL) publication-title: Blood – volume: 34 start-page: 3197 issue: 12 year: 2020 end-page: 205 article-title: Second cancer incidence in CLL patients receiving BTK inhibitors publication-title: Leukemia – volume: 9 start-page: 1481 year: 2008 end-page: 94 article-title: Intrinsic and treatment‐related immune alterations in chronic lymphocytic leukaemia and their impact for clinical practice publication-title: Expert Opin Pharmacother – volume: 327 start-page: 557 year: 2003 end-page: 60 article-title: Measuring inconsistency in meta‐analyses publication-title: BMJ – volume: 112 start-page: 188 year: 2008 end-page: 95 article-title: Constitutive activation of distinct BCR‐signaling pathways in a subset of CLL patients: a molecular signature of anergy publication-title: Blood – volume: 30 start-page: 2019 year: 2016 end-page: 25 article-title: Effect of first‐line treatment on second primary malignancies and Richter's transformation in patients with CLL publication-title: Leukemia – volume: 373 start-page: 2425 year: 2015 end-page: 37 article-title: Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia publication-title: N Engl J Med – volume: 6 year: 2009 article-title: Preferred reporting items for systematic reviews and meta‐analyses: the PRISMA statement publication-title: PLoS Med – volume: 395 start-page: 1278 year: 2020 end-page: 91 article-title: Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment‐naive chronic lymphocytic leukaemia (ELEVATE‐TN): a randomised, controlled, phase 3 trial publication-title: The Lancet – volume: 45 start-page: 507 year: 2004 end-page: 13 article-title: Veterans with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) have a markedly increased rate of second malignancy, which is the most common cause of death publication-title: Leuk Lymphoma – ident: e_1_2_7_3_1 doi: 10.1056/NEJMoa1509388 – ident: e_1_2_7_12_1 doi: 10.1016/S0140-6736(20)30262-2 – ident: e_1_2_7_6_1 doi: 10.1002/hon.54_2629 – ident: e_1_2_7_5_1 doi: 10.1517/14656566.9.9.1481 – ident: e_1_2_7_8_1 doi: 10.1080/10428190310001612939 – ident: e_1_2_7_7_1 doi: 10.1002/sim.1186 – ident: e_1_2_7_9_1 doi: 10.1038/leu.2016.113 – ident: e_1_2_7_4_1 doi: 10.1056/NEJMoa1509981 – ident: e_1_2_7_10_1 doi: 10.1371/journal.pmed.1000097 – ident: e_1_2_7_11_1 doi: 10.1182/blood-2007-09-111344 – ident: e_1_2_7_2_1 doi: 10.1038/s41375-020-0987-6 – ident: e_1_2_7_13_1 doi: 10.1182/blood-2013-07-515361 |
| SSID | ssj0002315631 |
| Score | 2.1940813 |
| SecondaryResourceType | review_article |
| Snippet | Acalabrutinib is a second generation Bruton's tyrosine kinase inhibitor and was recently approved in the treatment of chronic lymphocytic leukaemia. We... Abstract Acalabrutinib is a second generation Bruton's tyrosine kinase inhibitor and was recently approved in the treatment of chronic lymphocytic leukaemia.... Abstract Acalabrutinib is a second generation Bruton's tyrosine kinase inhibitor and was recently approved in the treatment of chronic lymphocytic leukaemia.... |
| SourceID | doaj pubmedcentral proquest crossref pubmed wiley |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Publisher |
| StartPage | 115 |
| SubjectTerms | acalabrutinib Bias Bruton's tyrosine kinase Cancer therapies chronic lymphocytic leukaemia Chronic lymphocytic leukemia Clinical trials Enzyme inhibitors Leukemia Medical prognosis Meta-analysis nonmelanoma skin cancers Protein-tyrosine kinase Review Risk factors second primary malignancies Skin cancer Systematic review |
| SummonAdditionalLinks | – databaseName: Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3LbtNAFB2hLhAbRHmmFDRICLULq45fGbMLEVVUtSxQK3VnXd8ZQ9rERnGy6K6fwM_xA3wJZ2ackAgqNuxGnli-vvfYc048c0aItyqJGC_-QVBW_SzACFEGJYVJwHmecm7YKOfTffYpG18kJ5fp5cZWX3ZOmLcH9ok7yiLFZPqDrCK8SI0m6AeOq7Ak6zUVeeET5hti6sqZuECXxP2V22wYHV3ZhauO526MP86m_2_c8s8pkpvU1Y09x4_Ew440yqEPdlfcM_Vjcf-s-yz-RPwYItNUzgGielL-vP3uVqgYLVsrd7X85i0l5Ayk-4vfj7eVhI7aLnGbUt3MSLbXk1qyBcG8lWh2jquttH_VSvYmunJ6g_I3fLOwbbO8JjObkDwYnZ4evpdD-dsYWvpFMe4yM7MgREWdAYpsKokhUjfAGILsZstP0XR7iLTy4PPovD18Ki6OP56PxkG3X0OAcseoNHMK_UV6YChVIZmw4pwZHEVpMqg7uAD4Y5nGHOky0VXMgETOKCSnpAbxM7GD-zYvhMyThDGAah05i8JMEahezJUxSmUmSnrizaqKRZfDwhswR4WttFU0PfHBlnfdb4203QHAq-jgVfwLXj2xvwJH0T3dbWFFdWq1_R3dEKUg4tCKCHPdjZTabzFUm2Zpf5P3EyQpR5jPPdTWgcaWFIY5zh5sgXDrTrZ76slXZw0O8Y2TVU-8c3C9MzfFyXhot3Tf-x85eikeRHamj5vLvi92FvOleQWqtihfu6fyF-HPQyo priority: 102 providerName: Directory of Open Access Journals – databaseName: AUTh Library subscriptions: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3NbhMxELYglRAXxD-BgoyEUHtYdf_j5YLSqFVUtRWqWqm31ezY24YmuyWbHHrjEXg5XoAnYcbrLI2g3Kx4V5n1jD3f2ONvhPig4hBp4R94RRmkHnmIwivAjz3MsgQzg0ZZnu6j43R8Fh-cJ-duw61xaZWrNdEu1LpG3iPfYaRP6IYA-Ofrbx5XjeLTVVdC477YCClS8HtiY3fv-MtJt8tC6CVJo2DFOuuHO1_5AqvFu7f8kKXr_xfG_DtV8jaEtT5o_7F45MCjHLbafiLumeqpeHDkjsefiZ9DGnEo5mRM1aT49f2HvalitGw47NXyuqWWkDMC3xdtXd5GAnVUfNVtClU9A9lcTSqJbAzzRlLTMa82krdsJbZkunJ6Q2ZQ482C22Z5BWY2Abk1Ojzc_iSH8g9BtGwvx9i_mZkFkFTgiFBkXUpylbomWyMhXdb8lJq2lkgjt05Gp832c3G2v3c6GnuuboNHao9I44gJxWGgBwYS5YPxS8wQCasoDYb0T5iAcGSRRBjqItZlhGQaGdLqgAmoQfRC9Oi7zSshszhGcqRah5aqMFVAkC_C0hilUhPGffF-pcXcjWHeEjGHOWuaI5u-2GX1dv1MqG1_qOcXuZufeRoqBBMM0hLIXxsNFKZiVPoFMKVZGPTF5so4cjfLm5yD64Rj_Du6O5MlMbtuGlI-k4HK1Et-JgtiGqSMxHzZmlonaMTg0M_o7cGaEa59yXpPNbm0FOEUhNPLqi8-WnO9c2zyg_GQS7u__r_8b8TDkHN5bLb6pugt5kvzlsDYonjnZtxv5iw8Fg priority: 102 providerName: ProQuest – databaseName: Wiley-Blackwell Titles (Open access) dbid: 24P link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1db9MwFLVgSIgXxDcdAxkJoe0hWup881YqpmraEEKbtLfo2nG2sjZBTfuwt_0E_hx_gF_CuU6aUcEk3qw6Vh3fc33PdexjId6loTKY-BNPl8PYQ4TQniY_9EyWRSazxqZOp_v4czw5DQ_PorNuVyWfhWn1IfoFN_YMN1-zg5Nu9m9EQ7_xSVT4-V1xjwVjWDdfhV_69RXwlih21xGqGGBAFIrX2rO-2l833ohGTrT_X0zz7w2TfxJZF4kOHomHHYWUo9bmj8UdWz0R94-7j-RPxc8Rxp30ApCqpvrX9Q93XsUWsuHkt5DfW4EJOQcFP29v520koaLiA28zquo5yeZyWknDkFg0EsVOf7WRvHArTSupK2dXAENtrpZctqtLsvMpyd3x0dHeBzmSNzLRsj0i4_5mbpeEXlEnhyLrUiJgFjUQh052e-dnKLobRRq5-3V80uw9E6cHn07GE6-7vcGD8QPY3ZgI2RgViaUo9cn6pcmMAWNJC7JAAZgB2KSOAqMKHRZlYACQzGCOMBGlSfBcbOG97UshszA0CKdFoZxgYZwSiF9gSmvTNLYqHIi3ayvm3RjmrRyzytnSnN8MxEc2b1_Pstruh3pxnndemscqNWSHSVwSorYtCMmqCUpfEwubqeFA7KzBkXe-3uScYkec6d9SjRQVtByZI7rZV2NI-csMVbZe8TPZMMQgZejmixZqfUcDpoh-htbJBgg33mSzpppeOKFwpOJonA7EewfXW8cmP5yM-IL37f998JV4oHhvj9u9viO2louVfQ1yttRvnBf-BuejO-k priority: 102 providerName: Wiley-Blackwell |
| Title | Acalabrutinib‐related second primary malignancies and nonmelanoma skin cancers in patients with chronic lymphocytic leukaemia (CLL): A systematic review and meta‐analysis of randomised controlled trials (RCTs) |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fjha2.146 https://www.ncbi.nlm.nih.gov/pubmed/35846092 https://www.proquest.com/docview/2549533831 https://www.proquest.com/docview/2619080862 https://www.proquest.com/docview/2691458096 https://pubmed.ncbi.nlm.nih.gov/PMC9175848 https://doaj.org/article/628cae176fa847eda104c3f0ba101821 |
| Volume | 2 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NTttAEB4RKiEuFf13S6OtVFVwMLHX_72FCBQhgiIEEjdrPV6DIbZRnBy48Qh9ub5An6Szazslarn0tvJa8njn25357NlvAb6GLkda-AMzyWzfpAiRmImwXBOjyMNIogy1TvfkzB9fuidX3tUGeN1eGF20j0l-UM6KgzK_0bWV9wUOujqxwXQyIopBcTMc9KBHAH1C0W-1fgtREsfuhGYtPrhVe1ZpRdiGLUfFWyvia1FIi_X_K8P8u1DyaQKrI9DxDrxsU0c2bEx8BRuyfA1bk_bn-Bv4OaTxFsmcoFTmya_HH3qfikxZrUhvyu4bYQlWUOp93ZzKWzNBHaXa6DYTZVUIVt_lJUMFhXnNqNnqrtZMfbBl2EjpstkDgaDCh4Vqy-WdkEUu2N7o9HT_OxuyP_LQrNkaox9TyIUgq0Qrg8KqjFGgTCtCGhnZ1szPqKlPEqnZ3vnoot5_C5fHRxejsdme2mCS0x3yN6JHLEykgRReaAlpZRghUqYSpkKS9ykjoCwy8RzkaeKmmYMEjAhpbUBPhIHzDjbpveUHYJHrIoXRNOVaqNAPBSV8DmZShqEvuWvAl86LcTuGcSPDzGPldMVrDDhU7l31KzltfaGaX8ctqGKfhyikHfiZoGgtU0EkFZ3MSoQSNOO2AbsdOOJ2jtexotaeYvjPdBM1pXScGCOZueqmIVV_ZEQpq6W6J7JdGqSIzHzfQG1laAdVA4I1EK69yXoPzRctEN7ODwO-abg-OzbxyXioDnb_-N-P-ATbXBX56DL2XdhczJfyM2Vpi6QPPe5O-_Di8Ohset7X3zr6eqb-BiFORy4 |
| link.rule.ids | 230,315,730,783,787,867,888,2109,11574,21400,27936,27937,33756,33757,43817,46064,46488,50826,50935,53804,53806,74630 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3NbhMxELaglYAL4rekFDASQu1h1f1fLxeURq1CSSJUpVJvK-_YW0KT3TabHHrjEXg5XoAnYcbrLI2g3Kx4V5n1jD3f2ONvGHsnQh9w4U-cvPBiBz1E7uTSDR1I0whSDVoYnu7hKO6fhsdn0ZndcKttWuVqTTQLtaqA9sj3CekjukEA_vHyyqGqUXS6akto3GWbRFWFwdfmweHoy0m7y4LoJYoDb8U66_r73-gCq8G7N_yQoev_F8b8O1XyJoQ1PujoEXtowSPvNtp-zO7o8gm7N7TH40_Zzy6OuMznaEzlJP_1_Ye5qaIVrynsVfyyoZbgMwTf501d3ppL7CjpqttUltVM8vpiUnIgY5jXHJuWebXmtGXLoSHT5dNrNIMKrhfU1ssLqWcTyXd7g8HeB97lfwiieXM5xvzNTC8kSiUtEQqvCo6uUlVoayikzZqfYtPUEqn57klvXO89Y6dHh-Ne37F1GxxUe4AaB4gwDpMq0TISrtRuASkAYhWhpEb9IyZAHJlHAfgqD1URAJpGCrg6QCRFEjxnG_jd-gXjaRgCOlKlfENVGAuJkC-AQmshYu2HHfZ2pcXMjmHWEDH7GWmaIpsOOyD1tv1EqG1-qObnmZ2fWewLkNpL4kKiv9ZKYpgKQeHmkijNfK_DdlbGkdlZXmcUXEcU49_S3Zositl245DSmYwsdbWkZ1IvxEFKUcytxtRaQQMCh26KbydrRrj2Jes95eSroQjHIBxfFh323pjrrWOTHfe7VNp9-__yv2H3--PhIBt8Gn1-yR74lNdjMtd32MZivtSvEJgt8td29v0GD6E_EA |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3NbhMxELYglSouiP8GSjESQu1hlf1fLxeUpo1CSaOqaqXeVt6xt4QmuyWbHHrjEXg5XoAnYcbrhEZQbla8q3jtz55v7PE3jL0ToQ-48CdOXnixgxYid3Lphg6kaQSpBi2MTvfxKB6ch0cX0YWNf6ptWOVyTTQLtaqA9sg7xPSR3SAB7xQ2LOLkoP_x-ptDGaTopNWm07jPNpIwDtwW29g_HJ2crnZckMlEceAtFWhdv_OVLrMa7nvLJhnp_n_xzb_DJm_TWWOP-o_YQ0skebcZ-cfsni6fsM1je1T-lP3sYu_LfIbAKsf5r-8_zK0VrXhNLrDi143MBJ8iEb9scvTWXGJFSdfeJrKsppLXV-OSAwFjVnMsWhXWmtP2LYdGWJdPbhASFdzMqawXV1JPx5Lv9obDvQ-8y_-IRfPmooz5m6meS2yVtKIovCo4mk1VIe6wkTaCfoJFk1ek5runvbN67xk77x-e9QaOzeHgIAQCHH2ACH0yqRItI-FK7RaQAiBvEUpqxALyA-SUeRSAr_JQFQEgTFLAlQIiKZLgOWvhd-stxtMwBDSqSvlGtjAWEulfAIXWQsTaD9vs7XIUM9uHWSPK7Gc00uTltNk-De-qnsS1zQ_V7DKzczWLfQFSe0lcSLTdWkl0WSEo3FySvJnvtdn2EhyZnfF1Ro52RP7-HdUr-GIzV9XYpXQ-I0tdLeiZ1Auxk1Js5osGaquGBkQU3RTfTtZAuPYl6zXl-IuRC0eHHF8WbfbewPXOvsmOBl1K8_7y_-1_wzZx4mXDT6PPr9gDn0J8TBD7NmvNZwv9GjnaPN-xk-83p3lDPg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Acalabrutinib%E2%80%90related+second+primary+malignancies+and+nonmelanoma+skin+cancers+in+patients+with+chronic+lymphocytic+leukaemia+%28CLL%29%3A+A+systematic+review+and+meta%E2%80%90analysis+of+randomised+controlled+trials+%28RCTs%29&rft.jtitle=EJHaem&rft.au=Htut%2C+Thura+W.&rft.au=Han%2C+Myat+M.&rft.au=Thein%2C+Kyaw+Z.&rft.date=2021-02-01&rft.pub=John+Wiley+and+Sons+Inc&rft.eissn=2688-6146&rft.volume=2&rft.issue=1&rft.spage=112&rft.epage=117&rft_id=info:doi/10.1002%2Fjha2.146&rft_id=info%3Apmid%2F35846092&rft.externalDBID=PMC9175848 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2688-6146&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2688-6146&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2688-6146&client=summon |